Babcock & Wilcoxの空売り状況は、投資家がBabcock & Wilcoxの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Babcock & Wilcox (NYSE:BW) 株価情報, 空売り情報

Babcock & Wilcox

Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.

Babcock & Wilcox Enterprises, Inc. Common Stock

Babcock & Wilcox Enterprises Inc

BorgWarner Inc

Better World Acquisition Corp Ordinary Shares

Better World Acquisition Corp Units (1 Ord & 1 War)

Better World Acquisition Corp Warrants (27/10/2025)

Bawag Group AG

Blue World Acquisition Corp

BLUE WORLD ACQUISITION CORP USD RTS

Blue World Acquisition Corp Units (1 Ord Class A & 1/2 War & 1 Right)

Blue World Acquisition Corp Warrants (10/01/2029)

Betawave Corp

BrainsWay Ltd. - American Depositary Shares

BrainsWay Ltd

Bridgewater Bancshares, Inc. - Common Stock

Bridgewater Bancshares Inc

Bridgewater Bancshares, Inc. - Depositary Shares, Each Representing a 1/100th Interest in a Share of 5.875% Non-Cumulative Perpetual Preferred Stock, Series A

BOWEN COKING COAL LTD NEW by BOWEN COKING COAL LTD.

Bowen Coking Coal Ltd

Blackwolf Copper and Gold Ltd

Bitwise Funds Trust Bitwise Web3 ETF

BW Energy Ltd

Boswell (JG) Co

Broadwind Inc

Amplify Commodity Trust Breakwave Tanker Shipping ETF

Bankwell Financial Group, Inc. - Common Stock

Bankwell Financial Group Inc

BrandywineGLOBAL Global Income Opportunities Fund Inc.

BrandywineGLOBAL - Global Income Opportunities Fund Inc

The Baldwin Insurance Group, Inc. - Class A Common Stock

The Baldwin Insurance Group Inc

BOARDWALKTECH SOFTWARE CP by Boardwalktech Software Corporation

Boardwalktech Software Corp

BW LPG Ltd

BW LPG Ltd ADR

Bowleven PLC

BROWNIE'S MARINE GRP INC by Brownie's Marine Group, Inc.

Brownie's Marine Group Inc

Bowman Consulting Group Ltd. - Common Stock

Bowman Consulting Group Ltd

BLACKROCK WRLD MNG TR by BlackRock World Mining Trust plc

Betterware de Mexico, S.A.P.I. de C.V. Ordinary Shares

Betterware de Mexico SAPI de CV

BORROWMONEY.COM INC by BorrowMoney.com inc.

BorrowMoney.com Inc

Verity Resources Ltd

Babcock & Wilcox Enterprises, Inc. 6.50% Senior Notes due 2026

BAWANG INTL GRP HLDG LTD by Bawang Intl Group Holding Ltd.

BW Offshore Ltd

WOWJOINT HLDGS LTD by Wowjoint Holdings Limited

Wowjoint Holdings Ltd

Baader Bank Aktiengesellschaft

BLUE WATER PETROLEUM CP by Blue Water Petroleum Corp.

Blue Water Petroleum Corp

BALWIN PROPERTIES LTD by Balwin Properties Ltd.

Balwin Properties Ltd

Babcock & Wilcox Enterprises, Inc. 8.125% Senior Notes due 2026

ETF Opportunities Trust Brendan Wood TopGun Index ETF

BOWLIN TRAVEL CENTERS INC by Bowlin Travel Centers, Inc.

Bowlin Travel Centers Inc

Bakken Water Transfer Services Inc

BLUE WATER VENTURES INC by Blue Water Ventures International, Inc.

Blue Water Ventures International Inc

SPDR Bloomberg International Treasury Bond ETF

BWX Technologies Inc

BWX LIMITED ORD by BWX Limited

SPDR Bloomberg Short Term International Treasury Bond ETF

Babcock & Wilcox Enterprises, Inc. 7.75% Series A Cumulative Perpetual Preferred Stock

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080323/So-Young-0625-900x600-1.png" alt="" class="wp-image-14853" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080323/So-Young-0625-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080323/So-Young-0625-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080323/So-Young-0625-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The cosmetic surgery specialist's shares have nearly doubled in the last two weeks as investors flock to its new business model centered on self-operated clinics
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>So-Young has delayed implementation of a planned reverse share split following a surge that has seen its stock price nearly double in the last two weeks</li>
<li>The cosmetic surgery specialist is shifting its business model from referring people to third-party clinics to operating its own facilities to give it better quality control</li>
</ul>
Cosmetic surgery specialist So-Young International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SY#NASDAQ">SY</a>) appears to be having second thoughts about its latest plan involving a makeover for its stock, which was ailing as recently as May 30 when it announced the equivalent of a 19.5-to-1 reverse share split. Such reverse splits are used by U.S.-listed companies to bring their prices back above the $1 level as required by New York Stock Exchange and Nasdaq listing rules.
So-Young's stock fell below the $1 mark on an extended basis last June, prompting the Nasdaq to notify it of failure to comply with listing requirements. Its reverse share split would have brought it back into compliance by raising its price well above the $1 mark, and was set to take effect on June 30.
But then the company's shares suddenly began to surge about two weeks ago, taking them above the $1 mark on June 17. They've continued to climb since then, and, at Tuesday's close of $1.71, have nearly doubled over the last two weeks. That sudden surge was most likely what prompted the company to&nbsp;<a href="https://www.prnewswire.com/news-releases/so-young-announces-extension-of-plan-to-implement-ads-ratio-change-302486910.html">announce</a>&nbsp;last Friday it was reconsidering its reverse share split decision. It said it needed "additional time to finalize preparations" for the move and would announce a new date in the future.
So, what's happening here?
While it's possible the recent rally is coming from speculators looking to make some quick money, a more likely reason is that investors are just now discovering So-Young's own internal makeover that has the potential to return it to strong growth. Even after the rally, So-Young's stock still trades at a relatively low price-to-sales (P/S) ratio of 0.85. That's still ahead of Chinese hair transplant specialist&nbsp;Yonghe Medical's&nbsp;0.32, but behind a more typical 1.73 for&nbsp;Perfect Medical&nbsp;(1830.HK), which operates centers in the more mature Hong Kong market.
Put simply, So-Young is discovering the importance of quality control, especially for something as sensitive as cosmetic surgery, where a few inexperienced doctors and shoddy surgeries can quickly spoil a company's reputation. In the past, So-Young was mostly an intermediary, helping to link consumers with the thousands of cosmetic surgery centers across China, and taking referral fees as its main revenue sources.
But that business proved problematic due to the difficulty of controlling quality among the many clinics on So-Young's network. Making matters worse for its core client base, health regulators in 2023 began requiring operators of all such centers to get licensed before being allowed to advertise their services. At that time, only about 13,000 such clinics were licensed, and a much larger 80,000 lacked any official qualifications, according to independent research.
Realizing the difficulty of operating in such an environment, So-Young made the decision about two years ago to start operating its own clinics where it could have complete control over the quality of not only its products, but also its personnel and service levels. That part of its business has developed quickly and looks likely to become its main revenue source in the next year or two.
"We believe the big key to our next phase hinges on developing our aesthetic center business with full control over the supply chain," said Chairman Jin Xing on the company's latest earnings call last month.
<h4 class="wp-block-heading">Rocky road</h4>
So-Young has traveled a rocky road since its New York IPO in May 2019, when it raised $180 million by selling shares for $13.80 apiece. The pandemic began less than a year later, putting huge pressure on its business as people put off cosmetic surgery for fear of being infected by Covid-19. As a result, the company's revenue went into reverse in 2022, falling 26% that year, before rebounding somewhat with the pandemic's end in 2023.
But even after the pandemic's end, the company was hit by the regulatory crackdown, causing its revenue to contract again by a milder 2% last year. The contraction hasn't ended yet, and So-Young's&nbsp;<a href="https://www.prnewswire.com/news-releases/so-young-reports-unaudited-first-quarter-2025-financial-results-302457679.html">latest results</a>&nbsp;show its revenue fell 6.7% in this year's first quarter to 297 million yuan ($41 million) from 318 million yuan a year earlier.
That drop was due to a 34% decline in the company's "information and reservations" services, which include the referral fees it receives from directing customers to clinics. That part of its business generated 143 million yuan in the first quarter, or just under half of its revenue for the period. By comparison, that part of the business brought in 217 million yuan a year earlier, when it accounted for more than two-thirds of the company's revenue.
While that part of its business was fading, the company's newer aesthetic treatment services from its growing chain of self-operated clinics was rapidly growing. Revenue from that part of the business jumped more than sixfold in the first quarter to 98.8 million yuan, making up one-third of its total, from just 15.2 million yuan a year earlier, when it accounted for just 5%.
The company said it expects that part of the business to keep growing rapidly as it opens new clinics, forecasting revenue from that segment of between 120 million yuan and 140 million in the second quarter. The company currently operates 23 aesthetic centers in major cities across China, among which only four have been open more than a year. It said on its earnings call it expects to open around 13 new clinics annually over the next few years.
"Our branded aesthetic centers continue to generate strong growth momentum, achieving triple-digit year-over-year revenue growth," said Jin. "We are confident this momentum will continue as we scale, enabling us to address key customer pain points and elevate the overall medical aesthetic experience."
We would tend to agree that So-Young's new business model looks better positioned for success, though it remains to be seen whether China's slowing economy and growing consumer caution might dampen demand for cosmetic surgery in general. But one thing that's more certain is that interest seems to be returning to the company's stock. As a result, we wouldn't be surprised to see So-Young ultimately cancel its previously announced reverse share split plan.

Equities

Global

Opinion

Signals

Trading Ideas

So-Young Shares Get A Makeover

WIIM

QuantumScape shares are trading higher after the company achieved a key 2025 milestone by successfully integrating its advanced Cobra separator process into baseline cell production.

Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing what it believes to be first-in-class therapies to treat mitochondrial diseases and combat age-related decline, and Launch One Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPAA#NASDAQ">LPAA</a>, "Launch One"))), a special purpose acquisition company focused on healthcare innovation, announce entering into a definitive business combination agreement (the "Business Combination Agreement").&nbsp; &nbsp;
Transaction highlights:
<ul>
<li>The proposed business combination (the "Business Combination") will create a publicly traded, clinical-stage biotechnology company focused on developing and commercializing Mitochondrial Augmentation Technology (MAT) – a proprietary platform designed to address a broad spectrum of diseases driven by mitochondrial dysfunction, from rare pediatric disorders to common adult conditions.</li>
<li>Upon closing of the transaction, the combined entity will operate under the name Mito US One Ltd. and is expected to be listed on Nasdaq.</li>
<li>The transaction is expected to provide Minovia with additional capital to facilitate accelerating its growth and development pipeline. This includes potentially reaching clinical and regulatory milestones, technology transfer, and the eventual commercial launch of the Company's longevity-focused offerings from its MAT platform.</li>
<li>The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions and shareholder approvals.</li>
<li>Launch One's trust account currently holds approximately $239.7 million in cash, a portion of which may be available to the combined company following the transaction, depending on the extent of redemptions by public shareholders. &nbsp;</li>
</ul>

LPAA

Minovia Therapeutics To Go Public Via Merger With Launch One Acquisition Corp., Forming Mito US One Ltd. To Advance Mitochondrial Therapies

AVAV

AeroVironment shares are trading higher after the company reported better-than-expected Q4 financial results.

Synchronoss Technologies, Inc. ("Synchronoss") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCR#NASDAQ">SNCR</a>), a global leader and innovator in personal cloud platforms for telecoms, today announced that it has achieved certification under the EU-U.S. Data Privacy Framework (DPF), administered by the U.S. Department of Commerce.
The DPF is a transatlantic data transfer mechanism that enables U.S.-based organizations to receive and process personal data from the European Union in compliance with European privacy laws, such as the General Data Protection Regulation (GDPR). The framework provides robust safeguards, enforcement mechanisms, and redress options to ensure personal data remains protected when transferred outside the EU.
The DPF certification reinforces Synchronoss's longstanding commitment to international privacy standards and strengthens its position as a trusted partner to Tier 1 telecom operators around the world.

News

SNCR

Synchronoss Technologies Secures Certification Under EU-U.S. Data Privacy Framework, Administered By U.S. Department Of Commerce

Guidance

PAYX

Paychex Sees FY2026 Adj EPS $1.29-$1.31 vs $5.31 Est; Sees Sales $6.491B-$6.602B vs $6.361B Est

Alliance Entertainment Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AENT#NASDAQ">AENT</a>), a premier global distributor and fulfillment partner of entertainment and pop culture collectibles, today announced the renewal of an exclusive North America distribution agreement with Wētā

AENT

Alliance Entertainment Renews Exclusive North America Distribution Deal With Wētā

Contracts

ZONE

CleanCore Solutions Announces Multi-Million Dollar Contract For Its Power Caddies And Fill Stations With A Logistics And Delivery Organization

In a recent interview, Sam Altman, the CEO of OpenAI, addressed the ongoing tensions with Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)and the recruitment efforts by Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>).
What Happened: On The Hard Fork, The New York Times&#8217; tech <a href="https://thenextweb.com/news/ai-openai-sam-altman-microsoft-antitrust-meta">podcast</a>, Altman confirmed that Microsoft, OpenAI&#8217;s largest investor, continues to back the AI company amid rumors of a strained relationship.
Altman disclosed that he had a &#8220;super nice call&#8221; with Microsoft&#8217;s CEO, Satya Nadella, where they discussed their future collaboration. He admitted to some points of tension but stressed that the partnership has been &#8220;really wonderfully good&#8221; for both parties.
Altman also addressed the recruitment efforts by Meta, led by CEO&nbsp;Mark Zuckerberg. Meta has reportedly extended nine-figure compensation packages to lure top technologists from OpenAI and other firms. &nbsp;When asked about Zuckerberg&#8217;s belief in Meta&#8217;s potential to develop &#8220;superintelligence,&#8221; Altman&#8217;s COO,&nbsp;Brad Lightcap, replied, &#8220;I think he believes he&#8217;s super intelligent.&#8221;
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/space/25/06/46090791/us-tests-radar-that-could-help-trumps-golden-dome-detect-missiles-over-1200-miles-report" target="_blank" rel="noreferrer noopener">US Tests Radar That Could Help Trump&#8217;s Golden Dome Detect Missiles Over 1,200 Miles: Report</a>
Why It Matters: The relationship between OpenAI and Microsoft has been <a href="https://www.benzinga.com/markets/tech/25/06/45966911/openai-vs-microsoft-inside-the-brewing-power-struggle-that-could-reportedly-explode-into-an-antitrust-showdown">under scrutiny</a> for some time. OpenAI was considering accusing Microsoft of anticompetitive practices, a move that could potentially strain their long-standing partnership.
Meanwhile, Meta&#8217;s aggressive <a href="https://www.benzinga.com/markets/tech/25/06/45988600/mark-zuckerbergs-meta-dangled-100-million-signing-bonuses-to-openai-team-members-says-sam-altman-happy-none-of-our-best-people-took-them">recruitment tactics </a>have also been in the spotlight. Meta offered $100 million compensation packages to lure top OpenAI talent, but Altman stated that the company&#8217;s best people are staying put because they believe more in achieving AGI.
The developments in the relationships between OpenAI, Microsoft, and Meta could have significant implications for the future of AI development and the tech industry as a whole.
On a year-to-date basis, shares of Microsoft soared 17.09%, while Meta surged 18.85%, as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://www.benzinga.com/markets/tech/25/06/46076895/microsofts-layoffs-news-july-2025-ai-investment-80-billion">Microsoft&#8217;s AI Gets $80 Billion—While Pink Slips Print By The Thousand</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

MSFT

Sam Altman Crushes OpenAI-Microsoft Feud Rumors, Hails 'Really Wonderfully Good' Bond With Satya Nadella

America's leading mission integrator, Science Applications International Corp. (NASDAQ:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=n9mC35wSX_iMo8LkQ59fF3pXXxuxiP8D5TdCV_MECizXxyGvI45TCj83U7L4CsHkSMF-kz1JadYgCtjh0ZAZIw==">SAIC</a>), has been awarded the Hyper-Innovative Operational Prototype Engineering (HOPE) 2.0 contract in support of the U.S. Air Force Tactical Exploitation of National Capabilities (AF TENCAP). This $928 million contract spans a five-year performance period and is set for a July 2025 program start.
A congressionally-mandated rapid-acquisition organization, AF TENCAP exploits existing air, space, cyber, national, and global Intelligence, Surveillance, and Reconnaissance (ISR) systems to accelerate delivery of innovative and secure warfighting capabilities across Air Force and Joint military missions for the Department of Defense (DoD).
The HOPE 2.0 contract&nbsp;integrates Intelligence Community capabilities with urgent DoD operational needs.&nbsp;SAIC will provide comprehensive Research, Development, Test, and Evaluation (RDT&amp;E) mission engineering services to help AF TENCAP create near program of record ready prototypes that lead to improved warfighting superiority and decision dominance in all domains.

SAIC

Science Applications Bags $928M, 5-Yr HOPE 2.0 Contract In Support Of U.S. Air Force Tactical Exploitation Of National Capabilities

Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) will release earnings results for the third quarter, after the <a href="https://www.benzinga.com/quote/MU/earnings">closing bell on Wednesday.</a>
Analysts expect the company to report quarterly earnings at $1.61 per share, up from 62 cents per share in the year-ago period. Micron Technology projects to report quarterly revenue at $8.85 billion, compared to $6.81 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Monday, Rosenblatt analyst Kevin Cassidy maintained Micron Technology with a Buy rating and maintained a $172 price target.
With the recent buzz around Micron Technology, some investors may be eyeing potential gains from the company's dividends too. As of now, Micron Technology offers an annual dividend yield of 0.36%, which is a quarterly dividend amount of 12 cents per share (46 cents a year).
To figure out how to earn $500 monthly from Micron Technology, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Micron's $0.46 dividend: $6,000 / $0.46 = 13,043 shares.
So, an investor would need to own approximately $1,668,330 worth of Micron Technology, or 13,043 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $0.46 = 2,609 shares, or $333,717 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
MU Price Action: Shares of Micron gained by 4.8% to close at $127.91 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46072226/top-3-real-estate-stocks-you-may-want-to-dump-in-june">Top 3 Real Estate Stocks You May Want To Dump In June</a></li>
</ul>
Photo: Shutterstock

Earnings

Long Ideas

Markets

How To Earn $500 A Month From Micron Technology Stock Ahead Of Q3 Earnings

D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) with a Buy and maintains $10 price target.

Price Target

Analyst Ratings

IMUX

D. Boral Capital Maintains Buy on Immunic, Maintains $10 Price Target

Health Care

General

TIVC

Tivic Health Completes Optimization Study For Its Non-Invasive Vagus Nerve Stimulation Device

As of June 25, 2025, two stocks in the utilities sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to<a href="https://pro.benzinga.com/"> Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Korea Electric Power Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEP#NYSE">KEP</a>)</h3>
<ul class="wp-block-list">
<li>Korea Electric Power reportedly kept electricity rates frozen for the third quarter. The company's stock jumped around 20% over the past five days and has a 52-week high of $12.68.</li>
<li>RSI Value: 82.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>KEP Price Action: Shares of Korea Electric Power gained 21.5% to close at $12.61 on Tuesday.</li>
<li>Edge Stock Ratings: 95.47 Momentum score with Value at 99.81. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/kep"><img loading="lazy" decoding="async" width="432" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25073006/image-378.png" alt="" class="wp-image-961452" style="width:344px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25073006/image-378.png 432w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25073006/image-378-300x126.png 300w" sizes="(max-width: 432px) 100vw, 432px" /></a></figure>
<h3 class="wp-block-heading">Genie Energy Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNE#NYSE">GNE</a>)</h3>
<ul class="wp-block-list">
<li>On May 6, Genie Energy posted first-quarter adjusted EPS of 42 cents up from 33 cents a year ago. Michael Stein, Chief Executive Officer of Genie Energy, said, &#8220;Our first quarter featured strong operational and financial results, highlighted by robust increases in revenue, profitability and cash generation compared to the year ago quarter.&#8221; The company's stock gained around 30% over the past month and <a href="https://www.benzinga.com/quote/GNE">has a 52-week high</a> of $28.00.</li>
<li>RSI Value: 91.2</li>
<li>GNE Price Action: Shares of Genie Energy gained 1.8% to close at $27.26 on Tuesday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>. 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46072226/top-3-real-estate-stocks-you-may-want-to-dump-in-june">Top 3 Real Estate Stocks You May Want To Dump In June</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Top 2 Utilities Stocks That May Fall Off A Cliff In Q2

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.
Shares of FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) fell sharply in today's pre-market trading following soft <a href="https://www.benzinga.com/quote/fdx/earnings">first-quarter guidance</a>.
FedEx reported fourth-quarter revenue of $22.2 billion, beating analyst estimates of $21.84 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of $6.07 per share, beating analyst estimates of $5.87 per share.
FedEx expects first-quarter adjusted earnings to be between $3.40 and $4 per share versus estimates of $4.15 per share. The company expects revenue to be flat to up 2% on a year-over-year basis in the first quarter.
FedEx shares dipped 5.4% to $216.85 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Torrid Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) dipped 29.4% to $3.59 in pre-market trading as the company announced the pricing of secondary offering of common stock and concurrent share repurchase.</li>
<li>Allot Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLT#NASDAQ">ALLT</a>) fell 9% to $8.75 in pre-market trading after the company announced the pricing of underwritten public offering of ordinary shares.</li>
<li>QXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) fell 6.9% to $21.87 in pre-market trading as the company announced the pricing of common stock offering.</li>
<li>Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) fell 6.6% to $43.75 in pre-market trading after the company announced the pricing of upsized public offering of common stock.</li>
<li>Standard BioTools Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) fell 4.9% to $1.1604 in pre-market trading. Standard BioTools recently announced a strategic sale of SomaLogic to Illumina.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) dipped 4.6% to $50.76 in pre-market trading as the company priced repurchase of convertible notes and registered direct offering of Class A common stock to fund convertible note repurchase.</li>
<li>Daktronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAKT#NASDAQ">DAKT</a>) fell 3.4% to $14.68 in pre-market trading following downbeat quarterly sales.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46072226/top-3-real-estate-stocks-you-may-want-to-dump-in-june">Top 3 Real Estate Stocks You May Want To Dump In June</a> </li>
</ul>
Photo via Shutterstock

Movers

ALLT

ASTS

CDTX

CURV

DAKT

FedEx Issues Soft Guidance, Joins Torrid Holdings, Allot And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hyliion.com%2F&amp;esheet=54281804&amp;newsitemid=20250625033843&amp;lan=en-US&amp;anchor=Hyliion+Holdings+Corp.&amp;index=1&amp;md5=d11f56361baac979f5fd561eea36ed23">Hyliion Holdings Corp.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYLN#NYSE">HYLN</a>), a developer of sustainable electricity-producing technology, today announced it has signed a non-binding Letter of Intent (LOI) with MMR Power Solutions, a subsidiary of MMR Group – a leading provider of custom electrical solutions for commercial, industrial and utility applications globally with 5000+ employees and over $6 billion in delivered projects. The LOI outlines plans for MMR to purchase three KARNO&#x2122; Power Modules from Hyliion, totaling up to 600 kW of stationary power output, with deployments expected to begin in the second half of 2026.
The units are expected to support MMR's growing customer base in the commercial and industrial sectors with efficient, scalable power solutions tailored to local operating conditions. Designed for high efficiency, low emissions, and extended uptime, the KARNO system will offer an alternative to traditional combustion-based generators for on-site, long-duration power needs.

HYLN

Hyliion Holdings Signs Non-Binding LOI With MMR Power Solutions, For MMR To Purchase Three KARNO Power Modules From Hyliion, Totaling Up To 600 Kw Of Stationary Power Output, With Deployments Expected To Begin In H2 2026

GCTK

Glucotrack shares are trading higher after the company and OneTwo Analytics presented final results of their first-in-human study for a continuous blood glucose monitor, which met all primary and secondary endpoints.

Biotech

Glucotrack And OneTwo Analytics Present Final Results Of First-In-Human Study For Continuous Blood Glucose Monitor, Which Met All Primary And Secondary Endpoints

Chardan Capital analyst Keay Nakae maintains iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) with a Buy and maintains $5 price target.

IBIO

Chardan Capital Maintains Buy on iBio, Maintains $5 Price Target

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce the activation of the first clinical study site for its Serenta trial in patients with familial adenomatous polyposis (FAP). The trial, which is now enrolling, represents a significant milestone in the development of a potential new treatment option for FAP.
The Serenta trial (NCT06950385) is a randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of eRapa in individuals diagnosed with FAP. The first site, in the US, is now open and actively screening eligible participants.

Comments

Babcock & Wilcox

空売り

Babcock & Wilcox (NYSE:BW) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル